Patent ID: 7332631

Claim:
A method for treating an autoimmune disease involving Fc receptor activity comprising administering to a subject in need of treatment one or more compounds having the general formula II: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are each independently selected from H, halogen, NO 2 , CN, C 1-6 alkyl, CF 3 , aryl, heteroaryl, cylcoalkyl, cycloheteroalkyl, OCF 3 , OR18, SR18, OC 1-6 alkyl, OC 2-6 alkylNR18R19, Oaryl, Oheteroaryl, Ocycloalkyl, Ocycloheteroalkyl, OC 1-6 alkylaryl, OC 1-6 alkylheteroaryl, OC 1-6 alkylcycloalkyl, OC 1-6 cycloheteroalkyl, CO 2 R18, C 1-6 alkylCO 2 R18, CONR18R19, C 1-6 alkylCONR18R19, NR18R19, C 1-6 alkylNR18R19, NR20C 1-6 alkylNR18R19, C 1-6 alkylNR20C 1-6 alkylNR18R19, NR18COR19, C 1-6 alkylNR18COR19, C 1-6 alkylNR20CONR18R19, NR20CONR18R19, C 1-6 alkylNR18SO 2 R19, NR18SO 2 R19; R18, R19 are each independently selected from H, C 1-4 alkyl, C 1-4 alkyl cycloheteroalkyl, aryl, heteroaryl, C 1-4 alkyl aryl, C 1-4 alkyl heteroaryl, or may be joined to form an optionally substituted 3-8 membered ring optionally containing an atom selected from O, S, NR21; R20, R21 are each independently selected from H, C 1-4 alkyl; R11, R12 are each independently selected from H, C 1-4 alkyl, halogen, OC 1-4 alkyl; and wherein the autoimmune disease is selected from the group consisting of rheumatoid arthritis, immune thrombocytopenia purpura, systemic lupus erythematosus and Crohn's disease.